[Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
Fenofibrate in doses of 300 mg/day was administered for 3 consecutive months to 31 patients with type IIa, IIb, III or IV hyperlipoproteinaemia (HLP). Mean plasma cholesterol levels decreased by 22% in type IIa (n = 15), by 19% in type IIb (n = 10), by 51% in type III (n = 2) and by 5% in type IV (n = 4) HLP. Mean plasma triglyceride levels were reduced by 32, 38, 60 and 52% respectively in these four types of HLP. Apo-A, measured in 11 patients with type IIa, HLP increased by up to 28% after three months' treatment, whereas alphalipoprotein cholesterol only slightly rose by a mean 11%. Apo-B decreased by 14%. Fenofibrate was well tolerated. Only one patient developed a pruriginous rash at the end of the treatment period.
D001053:Apolipoproteins / Q000097:blood*; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D002784:Cholesterol / Q000097:blood; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood; D006951:Hyperlipoproteinemias / Q000097:blood* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011422:Propionates / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D000960:Hypolipidemic Agents; D011422:Propionates; D014280:Triglycerides; D002784:Cholesterol; D011345:Fenofibrate
Activité du fénofibrate dans quatre types d'hyperlipoprotéinémie et sur les apoprotéines A et B dans le type IIa.